DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6bzxzj/metastatic_liver) has announced the addition of the "Metastatic Liver Cancer - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AB Science
- Arrowhead Research Corporation
- Mirna Therapeutics, Inc.
- Provectus Biopharmaceuticals, Inc.
- Transgene Biotek Limited
Drug Profiles
- masitinib
- Monoclonal Antibody Conjugate to Target CEA for Metastatic Liver, Colorectal Cancer and Solid Tumor
- MRX-34
- Oncolytic Virus for Liver Metastases and Primary Liver Tumors
- Peptide to Inhibit Hemofiltrate CC Chemokine for Metastatic Liver Cancer
- PSL-001
- PV-10
- Stem Cell Therapy for Oncology
- TBL-0404
For more information visit http://www.researchandmarkets.com/research/6bzxzj/metastatic_liver
